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Over the past few decades, there have been significant advancements in the imaging tech-
niques of positron emission tomography (PET†) and single photon emission tomography
(SPECT). These changes have allowed for the targeted imaging of cellular processes and
the development of hybrid imaging systems (e.g., SPECT/CT and PET/CT), which provide
both functional and structural images of biological systems. One area that has garnered
particular attention is angiogenesis as it relates to ischemic heart disease and limb ischemia.
Though the aforementioned techniques have benefits and consequences, they enable sci-
entists and clinicians to identify regions that are vulnerable to or have been exposed to is-
chemic injury via non-invasive means. This literature review highlights the advancements in
molecular imaging techniques and specific probes as they pertain to the process of angio-
genesis in cardiovascular disease.
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Along with other imaging modalities
such as ultrasound and magnetic resonance
imaging (MRI), positron emission tomogra-
phy (PET), and single photon emission to-
mography  (SPECT),  imaging  techniques
have continued to evolve over the last 30
years, advancing the assessment of cardio-
vascular diseases. These imaging modalities
each have advantages and disadvantages.
Ultrasound has traditionally been the most
widely available and relatively inexpensive
means for imaging of the cardiovascular sys-
tem without exposure to radiation; however,
this modality has limited penetration depth
and does not have molecular probes avail-
able that permit interrogation beyond the in-
travascular compartment. MRI is another
imaging method that does not expose pa-
tients to radiation, although it is much more
expensive. This modality has good spatial
resolution and tissue penetration, but much
lower sensitivity for targeted imaging than
nuclear imaging techniques such as PET and
SPECT. Additionally, MRI has a suscepti-
bility to motion artifacts and currently does
not have the availability of as many molec-
ular probes as PET and SPECT. PET and
SPECT imaging systems possess superior
sensitivity, and there is availability of a wide
range of imaging probes for in vivo analysis
of cellular processes. However, a disadvan-
tage associated with both of these modali-
ties is their lower resolution and exposure of
patients to ionizing radiation [1,2].  
PET and SPECT have been the tradi-
tional nuclear modalities used for in vivo im-
aging of molecular and cellular processes
[1-4]. More recent developments in nuclear
imaging in the last decade have seen the
emergence of hybrid imaging systems that
also incorporate the use of X-ray computed
tomography  (CT)  with  both  PET  and
SPECT,  providing  the  co-localization  of
both functional and anatomical information
for a wide range of clinical applications.
These hybrid PET/CT and SPECT/CT im-
aging systems offer unique insight into crit-
ical cellular processes contributing to the
development of a variety of cardiovascular
disease  states,  as  multiple  radiolabeled
probes are available that specifically target a
variety  of  molecular  and  biological
processes of interest [5-8]. Additionally, the
creation of hybrid imaging systems has fa-
cilitated the combination of high sensitivity
radiotracer-based imaging with high resolu-
tion CT imaging, allowing for co-localiza-
tion  of  function  images  with  anatomical
images. These hybrid systems permit atten-
uation correction, minimizing attenuation
artifacts from soft tissue, and correction of
partial volume effects, ultimately resulting
in enhanced quantification of radiotracers.
These imaging approaches ultimately will
result in better individualized health care as
physicians more accurately quantify molec-
ular signals within specific anatomical struc-
tures of interest. Additionally, the increased
availability of microPET and microSPECT
imaging systems should allow for enhanced
translational research from small animal pre-
clinical models of cardiovascular disease
into the clinical environment [9-13].  
Angiogenesis, or the growth of new
capillaries from existing microvessels, is a
specific process that can occur following is-
chemic injury and thus has gained attention
as a critical target within the cardiovascular
imaging  community  in  recent  years
[1,2,7,8,14]. The purpose of this review is to
focus on specific molecular imaging targets
directed at the process of angiogenesis in
cardiovascular disease. A PubMed search of
“imaging,  angiogenesis”  returned  nearly
3,000 results, with articles being selected
based on relevance to the topic at hand (i.e.,
PET and SPECT imaging). 
MolECulAR IMAgIng
Molecular imaging, in general, is de-
fined as the in vivo-targeted imaging of bio-
logical processes. This imaging approach
incorporates molecular probes that localize
to specific molecular events associated with
physiological or pathological processes [2,3].
The magnitude of these events occurring
within biological systems is assessed based
upon the magnitude of probe uptake within
the region of interest. The high sensitivity of
nuclear imaging systems contributes to the
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resolution information from X-ray CT con-
tributes important information related to the
anatomical localization of probe. Successful
molecular imaging relies on multiple factors,
such as the availability of the probe that is
specific  and  sensitive  to  the  molecular
process being examined, as well as the ap-
propriate instrumentation to allow for desir-
able visualization and quantification of probe
uptake [1]. The application of molecular im-
aging already has proven to be valuable for
those within the oncology community by as-
sisting with early detection and intervention
strategies [15]. Further development of the
molecular imaging approach should continue
to improve disease management for addi-
tional disease states by not only early identi-
fication and detection in vulnerable patient
populations, but also by facilitating the di-
rection of pharmacological, cell-based, and
genetic therapeutic regimens in the future.
One field of study within the molecular im-
aging community that continues to evolve is
targeted imaging of angiogenesis, a process
that plays a critical role both in tumor biol-
ogy and the repair following ischemic injury.
AngIogEnESIS
Angiogenesis is generally defined as
the development of new capillaries from
pre-existing  microvessels. This  complex,
multistep process involves a variety of cells,
along with both stimulatory and inhibitory
factors [16]. Commonly, differentiation of
angioblasts into endothelial cells leads to en-
dothelial cell sprouting [17]. Growth factors
serve to activate pre-existing endothelial cell
receptors, leading to the release of proteases
and regulating the degradation of the base-
ment membrane, ultimately allowing for the
release of endothelial cells from parent ves-
sels. Endothelial cell sprouting occurs as en-
dothelial cell proliferation and migration
into the extracellular matrix takes place with
the help of adhesion molecules and inte-
grins. These sprouting endothelial cells de-
velop into new vessels with the addition of
pericytes or vascular smooth muscle cells
(VSMCs), which serve to stabilize the de-
veloping vessel and regulate blood flow. In
addition to sprouting angiogenesis, splitting
angiogenesis, or intussusception, also exists.
In this form of angiogenesis, single vessels
are split into two as the capillary wall ex-
tends into the vessel lumen. Reorganization
of existing cells ultimately results in the for-
mation of an additional vessel lumen, which
splits from the parent vessel [16-19].  
Several conditions known to stimulate
the angiogenic process include ischemia, hy-
poxia, inflammation, shear stress, and trau-
matic  injury  [17].  Previous  research  has
largely focused on imaging of angiogenesis
within tumors [20-22], as well as skeletal
[9,23-25] and cardiac muscle [26-29] ex-
posed to surgically induced ischemia. The
addition  of  recently  developed  vessels
within these tissues has important clinical
implications, as they can ultimately lead to
increased perfusion to injured or ischemic
tissues [30]. 
A variety of factors have been found to
contribute to the process of angiogenesis fol-
lowing hypoxia-induced conditions, includ-
ing  hypoxia-inducible  factor  1  (HIF-1),
vascular endothelial growth factor (VEGF),
platelet-derived growth factor (PDGF), fi-
broblast  growth  factor-2  (FGF-2),  trans-
forming growth factor beta (TGF-β), and
angiopoietins (interacting with their Tie re-
ceptors)  [31-34]. Through  the  actions  of
these angiogenic-induced factors, a number
of other important mediators are then sig-
naled, including endothelial cells, SMCs,
blood-derived macrophages, and circulating
stem cells [35]. Although various angiogen-
esis-stimulating factors exist, VEGF is con-
sidered the most potent and predominant
factor  [18,19].  VEGF  ligands,  of  which
there are four known isoforms, mediate their
angiogenic effects by binding to specific
VEGF receptors (VEGFR-1, VEGFR-2, and
VEGFR-3), leading to receptor dimerization
and subsequent intracellular signal trans-
duction via tyrosine kinases [20]. In addition
to the previously mentioned angiogenic fac-
tors, integrins also have been implicated in a
number of processes related to angiogene-
sis, including cell adhesion, migration, pro-
liferation, differentiation, and survival [36].
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erodimeric cell surface receptor, plays a sig-
nificant role in angiogenesis by allowing
cells to interact with the extracellular matrix,
contributing to the migration of endothelial
cells. Because of their important roles in an-
giogenesis, the αvβ3 integrin and VEGF
have been targeted for multiple molecular
imaging studies and remain as a focus of in-
terest [9,24,26,27,29,37].
MolECulAR IMAgIng oF 
AngIogEnESIS
Angiogenesis imaging can be catego-
rized as targeted at three major cell types: 1)
non-endothelial  cell  targets  (e.g.,  mono-
cytes, macrophages, and stem cells); 2) en-
dothelial cell targets (e.g., VEGF, growth
factor receptors, integrins, CD13, cell adhe-
sion molecules); and 3) extracellular matrix
proteins and matrix proteases [1,38]. Recent
techniques in nuclear medicine also have fo-
cused on the development of tracers target-
ing  the  ED-B  domain  of  a  fibronectin
isoform, as fibronectin plays an important
role in the binding of integrins and extracel-
lular matrix components during the process
of angiogenesis [39]. Additionally, targeted
imaging  of  stem  cell  therapy  is  another
emerging technique, which has been per-
formed in MRI [40,41], SPECT [42], and
PET [43-45]. The growth of this field should
further enhance future angiogenesis cell-
based therapy; however, many of the agents
used in nuclear imaging for this purpose are
not well studied and warrant further investi-
gation. The use of the contrast agents in
MRI for targeted imaging of angiogenesis is
also  gaining  interest,  as  they  have  been
shown to permeate the walls of angiogenic
capillaries and assist in targeted imaging of
integrins within areas of vascular growth
[21,46-48]. Targeted CT contrast agents may
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Figure 1. Myocardial origin of 64Cu-doTA-VEgF121 PET signal in a rat model of MI. a)
Coregistered images of microCT (left), PET (right), and fused PET/CT image (center) within
infarcted region of heart demonstrates that the 64Cu-DOTA-VEGF121 signal detected with
PET corresponds to anterolateral myocardium (PET and fused images, red arrow) and is
clearly separated from intercostal muscle layer (microCT image, white arrow). There is also
increased uptake in the surgical wound area (PET image, arrowhead). b) Representative
images of 64Cu-DOTA-VEGF121 (left), 18F-FDG (right), and 64Cu-DOTA-VEGF121/18F-FDG
fused image (middle). 18F-FDG imaging shows that surgical ligation of the coronary artery re-
sulted in lack of 18F-FDG uptake (yellow arrow) and that uptake of 64Cu-DOTA-VEGF121 oc-
curs in areas supplied by ligated coronary artery (turquoise arrow). The fusion of both images
results in complementation of 18F-FDG and 64Cu-DOTA-VEGF121 signals. There is also in-
creased uptake in the surgical wound area (arrowhead).  (reprinted with permission of [13]) offer a similar approach that could be com-
bined with targeted radiotracers using hybrid
PET/CT and SPECT/CT.
There has been significant focus on tar-
geted imaging of the αvβ3 integrin with lig-
and-like  peptidomimetics  or  the  RGD
(arginine-glycine-aspartate) peptide sequence
[9,12,24,26,27,29,49-52]. The RGD binding
motif for integrins has led to the development
of multiple molecular probes that have ad-
vanced the in vivo imaging of angiogenesis.
Various improvements in integrin-targeted
constructs also have increased the optimiza-
tion of pharmacokinetics and binding charac-
teristics.  More  recent  developments  in
nanoparticle technology are enhancing the
ability to deliver various imaging agents to
targeted regions of interest, ultimately lead-
ing to improved sensitivity and image quality
[1]. This review will focus on more estab-
lished methods for targeted imaging of the
angiogenic process. Most notably, this paper
will detail the altered expression of VEGF re-
ceptors and αvβ3 integrins.
VEgF RECEPToRS
VEGF has been identified as an impor-
tant stimulator of the angiogenic process
[19]. Because of this, multiple SPECT and
PET molecular probes have been developed
for targeted imaging of VEGF receptors in
tumor, peripheral limb, and myocardial an-
giogenesis  (Table  1).  Specifically,  many
studies have focused on targeted imaging of
angiogenesis in animal models of induced
ischemia  [9,23,24,26,27,29,53].  Human
monoclonal anti-VEGF antibodies labeled
with radioiodine (124I and 123I) were exam-
ined in initial studies of VEGF using PET
and SPECT. Unfortunately, the preclinical
applications of these studies were limited by
slower than usual clearance rates of these
antibodies [54,55]. To address this short-
coming, new molecular probes were created.
This advancement targeting ligands served
as the foundation for more efficient investi-
gation and monitoring of the upregulation of
VEGF during angiogenesis. VEGF165 and
VEGF121 were designed for this purpose and
implemented in early imaging studies of
tumor angiogenesis. These isoforms proved
to be successful in patients when radiola-
beled with 123I [55].
In addition to targeted imaging of tumor
angiogenesis, peripheral angiogenesis also
has been examined in ischemia-induced an-
imal models [9,23,24,53]. A murine model
of hind limb ischemia-induced angiogenesis
has revealed that 64Cu-6DOTA-VEGF121 is
effective in PET imaging of VEGFR-2 [23].
VEGF121 labeled with 111In has also been de-
veloped as a targeting ligand for SPECT and
was successfully used to image peripheral
angiogenesis in a rabbit model of hind limb
ischemia [53]. Analysis with immunohisto-
chemistry revealed an increased expression
of the VEGF receptors KDR (VEGFR-2)
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Figure 2. Analysis of wild-type and enoS-knockout mice. a) Micro-SPECT/CT of mice
injected with 99mTc-NC100692 following right femoral artery ligation. Yellow arrows indicate
ischemic regions with increased 99mTc-NC100692 retention. b) Serial images were ana-
lyzed and ischemic-to-nonischemic 99mTc-NC100692 activity ratios calculated. Solid bars
represent eNOS -/- knockout. Striped bars represent eNOS +/+ wild-type. 
*P < 0.05 vs. wild-type. #P <0.05 vs. baseline. (reprinted with permission of [9]).and Flt-1 (VEGFR-1) within skeletal mus-
cle exposed to hypoxia post-femoral artery
excision.  However,  substantially  larger
biodistribution of the radiotracer (approxi-
mately 20-fold higher) in multiple organs
systems (liver, kidneys) was evident when
compared to the ischemic limb. Possible ex-
planations for this disparity may be associ-
ated with VEGF receptor or macrophage
density  within  different  regions  or  may
closely correspond to particle size or coat-
ing [2,56,57].
A rat model of myocardial infarction
(MI) also has revealed enhanced angiogen-
esis through targeted PET imaging with the
tracer  64Cu-6DOTA-VEGF121 (Figure  1)
[13]. Following left coronary artery ligation,
hearts were imaged with microSPECT and
microCT at various time points to examine
early angiogenesis in ischemic territories of
the infarcted heart. Imaging demonstrated
that tracer signal was increased within the
infarcted region, which was indicated by de-
creased fluorodeoxyglucose (18F-FDG) up-
take,  an  established  marker  of  cellular
viability.  The  increased  signal  of  64Cu-
6DOTA-VEGF121 peaked at three days post-
MI and corresponded to post-mortem tissue
analysis of VEGF receptor expression, as in-
dicated by immunoflourescence microscopy.
In addition to targeted imaging of angiogen-
esis post-MI, the same VEGF121 isoform has
been successfully used to image tumor an-
giogenesis in a mouse model in PET [58]
and to develop single-chain technetium-la-
beled VEGF-based probes that are capable
of assessing tumor associated angiogenic
vasculature in PET and SPECT [59,60].
The development of a cardiac-specific
reporter in microPET imaging of rats may
offer insight into an additional therapeutic
route via a gene expression system [11,61-
63]. This system targets specific sites of the
cardiovascular system for the delivery of
angiogenic factors, therapeutic gene vec-
tors, and stem cells, with the ultimate goal
of stimulating angiogenesis within the re-
gion of interest. A previous study has used
a similar type of gene technology to iden-
tify the expression of VEGF121 in porcine
myocardium with PET-CT following aden-
oviral transfer [61]. Ultimately, this system
could lead to targeted therapeutic interven-
tions  while  also  incorporating  an  estab-
lished  imaging  modality  for  clinical
assessment.
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Table 1. A Summary of Molecular Probes used for non-invasive Imaging of
Angiogenesis.
Marker
VEGF
VEGF
VEGF
VEGF
VEGF
VEGF
VEGF
αvβ3
αvβ3
αvβ3
Probe
124I-VG76e
123I-VEGF165
111In-VEGF121
64Cu-VEGF121
64Cu-VEGF121
99mTc-scVEGF
64Cu-scVEGF
111In-RP748
111In-RP748
18F-AH111585
Imaging Modality
PET
SPECT
SPECT
PET
PET
SPECT
PET
SPECT
SPECT
PET
Biologic Target
Tumor angiogenesis
Tumor angiogenesis
Peripheral limb angiogenesis
Tumor angiogenesis
Myocardial angiogenesis
Peripheral limb angiogenesis
Tumor angiogenesis
Tumor angiogenesis
Myocardial angiogenesis
Tumor angiogenesisαVβ3 InTEgRIn
The αvβ3 integrin is found in abun-
dance on the surface of proliferating en-
dothelial  cells  and  is  a  consistent  and
specific marker of ongoing angiogenesis [4].
For this reason, targeted molecular imaging
of the αvβ3 integrin presents a novel nonin-
vasive approach for the assessment of an-
giogenesis. Early research focused on MRI
of the αvβ3 integrin with a paramagnetic-la-
beled monoclonal antibody to examine an-
giogenesis in a rabbit model of squamous
cell carcinoma [21]. However, poor clear-
ance of this antibody limited its translation
into future studies. Since then, development
of RGD peptides with high affinities for the
αvβ3 integrin has led to the advancement of
a variety of radiotracers suitable for the as-
sessment  of  angiogenesis  in  PET  and
SPECT imaging (Table 1) [50,64,65]. Addi-
tionally, the peptidomimetic 111In-RP748 has
shown a high affinity to the αvβ3 integrin
and has been successfully incorporated in
multiple studies [26,28]. Specifically, 111In-
RP748 has shown increased levels of uptake
within localized regions of decreased perfu-
sion in the myocardium of rodent and canine
models of myocardial infarction, as assessed
by SPECT imaging [26,28]. In these studies,
imaging with 111In-RP748 confirmed that in-
creased αvβ3 integrin activity was present
within the myocardium at both early (acute)
and late (3 weeks) time points post-infarc-
tion [26,28]. Given these results, targeted
imaging of integrin activation appears to
provide a useful technique that can be trans-
lated to the clinical setting for the detection
of angiogenesis post-myocardial infarction.
In support of this argument, the PET imag-
ing tracer 18F-Galakto-RGD targeted at inte-
grin  activation  previously  has  been
successfully used to image angiogenesis in a
patient 2 weeks post-myocardial infarction
[51]. 
99mTc-NC100692 (maraciclatide®) is a
technetium-labeled cyclic RGD peptide that
has been used in a variety of SPECT studies
to  noninvasively  assess  angiogenesis  [2].
The NC100692 compound has a high affin-
ity for the αvβ3 integrin, is metabolically sta-
ble, and has a biodistribution and kinetics
that are favorable for SPECT imaging. In-
creased focal activity of  99mTc-NC100692
has been demonstrated with SPECT at 3 and
7  days  post-femoral  artery  ligation  in  a
murine model of hind limb ischemia [24].
These results were further confirmed by the
close correlation of ex vivo tissue analysis
(gamma counting) and immunofluorescence
staining. A  similar  study  using  a  murine
model of hind limb ischemia examined pe-
ripheral angiogenesis in wild-type and en-
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Figure 3. In vivo microSPECT-CT imag-
ing and radiotracer quantification post-
myocardial infarction. a) Thallium-201
perfusion (top row, green) and αvβ3 inte-
grin targeted imaging (middle row, red) with
SPECT-CT in an IGF-1 treated rat at 4
weeks post-MI. Bottom row represents
fused image with reference contrast CT
image (grayscale). b) Gamma count pro-
files of thallium-201 (open circles) and
99mTc-NC100692 (solid circles) from middle
myocardial sections. (reprinted with per-
mission of [29])dothelial nitric oxide synthase (eNOS) defi-
cient animals with microSPECT-CT (Figure
2) [9]. This study, directed at serial quantita-
tive evaluation of angiogenesis, revealed de-
creased  uptake  of  the  compound  within
ischemic regions of the eNOS deficient mice
when compared to wild-type. Both groups,
however, exhibited the largest retention of
99mTc-NC100692 at 7 days post-femoral ar-
tery  occlusion,  as  indicated  by  ex  vivo
gamma counting of ischemic tissue. Other
studies using microSPECT-CT have con-
firmed the uptake of 99mTc-NC100692 within
mice [12] and rats [29,52] following surgi-
cally  induced  myocardial  infarction.  Do-
brucki  et  al.  used  99mTc-NC100692
microSPECT imaging to evaluate the effects
of gene therapy directed at stimulating an-
giogenesis. In this study, focal uptake of
99mTc-NC100692 was seen in the peri-infarct
region in association with accelerated angio-
genesis induced by intramyocardial injection
of a viral vector to upregulate expression of
insulin-like growth factor (IGF-1) in rats,
with further validation provided via gamma
counting of heart tissue (Figure 3) [29]. The
clinical translation of cardiovascular SPECT
imaging with 99mTc-NC100692 was recently
shown (Figure 4) and demonstrated the fea-
sibility and applicability of this targeted im-
aging  approach  for  broad  scale  clinical
application in ischemic heart disease [66]. 
The development of an αvβ3 integrin
targeted  nanoprobe  also  provides  a  new
technique for the detection of in vivo angio-
genesis with PET [67]. The nanoprobe al-
lows for labeling with isotopes while also
having a shell that is decorated with an RGD
peptides to confer specificity to the αvβ3 in-
tegrin [4]. This work has demonstrated a
more favorable biodistribution of the tar-
geted nanoprobe and retained specificity to
regions  of  ischemia  when  applied  in  a
murine model of hind limb ischemia (Figure
5) [67]. Ex vivo analysis by imaging and his-
tology has confirmed the effectiveness of
this nanoprobe for assessment of angiogen-
esis. This nanoprobe also may allow for tar-
geted drug delivery. Further development
and application of this nanotechnology to
angiogenesis imaging will offer a promising
new approach with the potential for transla-
tion of novel theranostics into clinical prac-
tice.
ConCluSIonS 
In summary, PET and SPECT imaging
can provide molecular targeted approaches
for the early in vivo assessment of biological
processes that precede the physiological or
anatomical manifestation of a disease. Re-
search has shown that these molecular im-
aging approaches offer unique opportunities
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Figure 4. Targeted im-
aging of angiogenesis
with SPECT in a pa-
tient 3 weeks post-my-
ocardial infarction.
Short (a) and long-axis
(b) views of enhanced
αvβ3 integrin signal (ar-
rowheads) within in-
fracted region, with
corresponding 99mTc-
MIBI perfusion images.
Images courtesy of Drs.
Johan Verjans and
Leonard Hofstra, uni-
versity Hospital, Maas-
tricht, the Netherlands.
(reprinted with permis-
sion of [66])for evaluation of the processes that regulate
cardiovascular disease pathogenesis, pro-
gression, and therapeutic intervention. Ad-
ditionally, these imaging modalities have
provided methods for the noninvasive as-
sessment of angiogenesis during instances
of myocardial and limb ischemia. The de-
velopment of novel molecular probes and
hybrid imaging systems continue to increase
the potential for translational research from
small and large animal studies into clinical
practice. The high sensitivity of PET and
SPECT  images  now  can  be  co-localized
with high resolution X-ray CT anatomical
images to better identify and quantify radio-
tracer uptake within vulnerable regions of
the heart and vasculature. Although these
systems have expanded the possibility for
application of molecular imaging into the
clinical setting, these systems still need to be
optimized and corrected for complicating
cardiac and respiratory motion. The poten-
tial for additional exposure to radiation from
CT imaging is also a cause for concern with
these hybrid imaging systems. Despite these
imperfections, molecular imaging with new
hybrid imaging technology offers a promis-
ing, unique approach for translating targeted
imaging of biological processes within the
cardiovascular system to humans. Pre-clini-
cal animal studies investigating ischemic tis-
sues might offer insight into the future of
treatment and targeted imaging. Many clin-
ical trials, to this point in time, have relied
on clinical endpoints or the evaluation of the
indirect effects of therapy on physiological
indices like tissue perfusion and function.
The continuing development of more sensi-
tive, noninvasive imaging modalities such
as PET and SPECT may someday confirm
the delivery of therapeutic angiogenic agents
and directly monitor progression of angio-
genesis within targeted tissues, providing
novel methods for optimizing therapeutic in-
terventions in patients suffering from vari-
ous forms of cardiovascular disease. 
REFEREnCES
1.  Dobrucki LW, de Muinck E, Lindner J, Sinusas
AJ. Approaches to multimodality imaging of
angiogenesis.  J  Nucl  Med.  2010;51(Suppl
1):66S-79S.
2.  Dobrucki LW, Sinusas AJ. PET and SPECT
in cardiovascular molecular imaging. Nature
reviews. Cardiology. 2010;7(1):38-47.
3.  Sinusas AJ, Thomas JD, Mills G. The future
of molecular imaging. JACC Cardiovasc Im-
aging. 2011;4(7):799-806.
4.  Morrison AR, Sinusas AJ. Advances in ra-
dionuclide imaging in myocardial biology. J
Nucl Med. 2010;17(1):116-34.
5.  Dobrucki LW, Sinusas AJ. Molecular imag-
ing. A new approach to nuclear cardiology. Q
J Nucl Med Mol Imaging. 2005;49(1):106-
115.
6.  Dobrucki LW, Sinusas AJ. Molecular cardiovas-
cular imaging. Curr Cardiol Rep. 2005;7(2):130-
5.
83 Stacy et al.: Targeted molecular imaging of angiogenesis
Figure 5. PET/CT imaging of angiogenesis in a murine model of hindlimb ischemia.
a) Non-targeted dendritic nanoprobes (bottom center). b) Higher uptake of αvβ3 -targeted
dendritic nanoprobes in ischemic hindlimb (left side of image) than in control hindlimb
(right side of image). (reprinted with permission of [67])7.  Dobrucki LW, Sinusas AJ. Cardiovascular
molecular  imaging.  Semin  Nucl  Med.
2005;35(1):73-81.
8.  Dobrucki LW, Sinusas AJ. Imaging angio-
genesis. Curr Opin Biotechnol. 2007;18:90-6.
9.  Dobrucki  LW,  Dione  DP,  Kalinowski  L,
Dione D, Mendizabal M, Yu J, et al. Serial
noninvasive targeted imaging of peripheral
angiogenesis: validation and application of a
semiautomated quantitative approach. J Nucl
Med. 2009;50(8):1356-63.
10. Razavian M, Marfatia R, Mongue-Din H,
Tavakoli S, Sinusas AJ, Zhang J, et al. Inte-
grin-Targeted Imaging of Inflammation in
Vascular Remodeling. Arterioscler Thromb
Vasc Biol. 2011;31(12):2820-6.
11. Inubushi M. Positron-Emission Tomography
Reporter Gene Expression Imaging in Rat
Myocardium. Circulation. 2002;107(2):326-
32.
12. Lindsey  ML,  Escobar  GP,  Dobrucki  LW,
Goshorn DK, Bouges S, Mingoia JT, et al.
Matrix metalloproteinase-9 gene deletion fa-
cilitates angiogenesis after myocardial in-
farction. Am J Physiol Heart Circ Physiol.
2006;290(1):H232-H239.
13. Rodriguez-Porcel M, Cai W, Gheysens O,
Willmann JK, Chen K, Wang H, et al. Imag-
ing of VEGF receptor in a rat myocardial in-
farction  model  using  PET.  J  Nucl  Med.
2008;49(4):667-73.
14. Sinusas AJ. Imaging of angiogenesis. J Nucl
Cardiol. 2004;11:617-33.
15. Seaman ME, Contino G, Bardeesy N, Kelly
KA. Molecular imaging agents: impact on di-
agnosis and therapeutics in oncology. Expert
Rev Mol Med. 2010;12:e20.
16. Mitsos S, Katsanos K, Koletsis E, Kagadis
GC, Anastasiou N, Diamantopoulos A, et al.
Therapeutic angiogenesis for myocardial is-
chemia revisited: basic biological concepts
and focus on latest clinical trials. Angiogen-
esis. 2012;15(1):1-22.
17. Fam NP, Verma S, Kutryk M, Stewart DJ.
Clinician guide to angiogenesis. Circulation.
2003;108(21):2613-8.
18. Simons M. Angiogenesis: where do we stand
now? Circulation. 2005;111(12):1556-66.
19. Carmeliet P, Jain RK. Molecular mechanisms
and clinical applications of angiogenesis. Na-
ture. 2011;473(7347):298-307.
20. Bruce  D,  Tan  PH.  Vascular  endothelial
growth factor receptors and the therapeutic
targeting of angiogenesis in cancer: where do
we  go  from  here?  Cell  Commun  Adhes.
2011;18(5):85-103.
21. Sipkins  DA,  Cheresh  DA,  Kazemi  MR,
Nevin LM, Bednarski MD, Li KC. Detection
of tumor angiogenesis in vivo by alphaV-
beta3-targeted magnetic resonance imaging.
Nat Med. 1998;4(5):623-6.
22. Streeter J, Gessner R, Tsuruta J, Feingold S,
Dayton P. Assessment of molecular imaging
of angiogenesis with three-dimensional ul-
trasongraphy. Mol Imaging. 2011;10(6):460-
8.
23. Willmann JK, Chen K, Wang H, Paulmuru-
gan R, Rollins M, Cai W, et al. Monitoring of
the biological response to murine hindlimb
ischemia  with  64Cu-labeled  vascular  en-
dothelial growth factor-121 positron emission
tomography. Circulation. 2008;117(7):915-
22.
24. Hua J, Dobrucki LW, Sadeghi MM, Zhang J,
Bourke BN, Cavaliere P, et al. Noninvasive
imaging of angiogenesis with a 99mTc-la-
beled peptide targeted at alphavbeta3 integrin
after murine hindlimb ischemia. Circulation.
2005;111(24):3255-60.
25. Buschmann IR, Voskui M, van Royen N,
Hoefer IE, Scheffler K, Grundmann S, et al.
Invasive  and  non-invasive  evaluation  of
spontaneous arteriogenesis in a novel porcine
model for peripheral arterial obstructive dis-
ease. Atherosclerosis. 2003;167(1):33-43.
26. Kalinowski L, Dobrucki LW, Meoli D, Dione
D, Sadeghi MM, Madri J, et al. Targeted im-
aging of hypoxia-induced integrin activation
in myocardium early after infarction. J Appl
Physiol. 2008;104(5):1504-12.
27. Dobrucki L, Meoli D, Hu J, Sadeghi M, Si-
nusas A. Regional hypoxia correlates with the
uptake of a radiolabeled targeted marker of
angiogenesis in rat model of myocardial hy-
pertrophy  and  ischemic  injury.  J  Physiol
Pharmacol. 2009;60(Suppl 4):117-23.
28. Meoli  D,  Sadeghi  M,  Krassilnikova  S,
Bourke B, Giordano F, Dione D, et al. Non-
invasive imaging of myocardial angiogene-
sis  following  experimental  myocardial
infarction. J Clin Invest. 2004;113(12):1684-
91.
29. Dobrucki L, Tsutsumi Y, Kalinowski L, Dean
J, Gavin M, Sen S, et al. Analysis of angio-
genesis induced by local IGF-1 expression
after  myocardial  infarction  using  mi-
croSPECT-CT imaging. J Mol Cell Cardiol.
2010;48(6):1071-9.
30. Schaper W. Collateral circulation: past and
present. Basic Res Cardiol. 2009;104(1):5-
21.
31. Shweiki D, Itin A, Soffer D, Keshet E. Vas-
cular endothelial growth factor induced by
hypoxia may mediate hypoxia-initiated an-
giogenesis. Nature. 1992;359(6398):843-5.
32. Brogi E, Schatteman G, Wu T, Kim EA, Var-
ticovski L, Keyt B, et al. Hypoxia-induced
paracrine regulation of vascular endothelial
growth factor receptor expression. J Clin In-
vest. 1996;97(2):469-76.
33. Banai S, Jaklitsch MT, Shou M, Lazarous DF,
Scheinowitz M, Biro S, et al. Angiogenic-in-
84 Stacy et al.: Targeted molecular imaging of angiogenesisduced enhancement of collateral blood flow
to  ischemic  myocardium  by  vascular  en-
dothelial growth factor in dogs. Circulation.
1994;89(5):2183-9.
34. Li J, Brown LF, Hibberd MG, Grossman JD,
Morgan JP, Simons M. VEGF, flk-1, and flt-
1 expression in a rat myocardial infarction
model  of  angiogenesis.  Am  J  Physiol.
1996;270(5 Pt 2):H1803-11.
35. Dufraine J, Funahashi Y, Kitajewski J. Notch sig-
naling regulates tumor angiogenesis by diverse
mechanisms. Oncogene. 2008;27(38):5132-7.
36. Schwartz MA, Schaller MD, Ginsberg MH. In-
tegrins: emerging paradigms of signal transduc-
tion. Ann Rev Cell Dev Biol. 1995;11:549-99.
37. Brooks PC, Clark RAF, Cheresh DA. Re-
quirement of Vascular Integrin alpha v beta 3
for Angiogenesis. Science. 1994;264:569-71.
38. Lake Tahoe invitation meeting 2002. J Nucl
Cardiol. 2003;10:223-57.
39. Haubner  R,  Beer  AJ,  Wang  H,  Chen  X.
Positron emission tomography tracers for im-
aging angiogenesis. Eur J Nucl Med Mol Im-
aging. 2010;37(Suppl 1):S86-S103.
40. Tallheden T,  Nannmark  U,  Lorentzon  M,
Rakotonirainy O, Soussi B, Waagstein F, et
al. In vivo MR imaging of magnetically la-
beled human embryonic stem cells. Life Sci.
2006;79(10):999-1006.
41. van  Laake  LW,  Passier  R,  Monshouwer-
Kloots J, Nederhoff MG, Ward-van Oost-
waard D, Field LJ, et al. Monitoring of cell
therapy and assessment of cardiac function
using  magnetic  resonance  imaging  in  a
mouse model of myocardial infarction. Nat
Protoc. 2007;2(10):2551-67.
42. Lappalainen RS, Narkilahti S, Huhtala T, Li-
imatainen T, Suuronen T, Narvanen A, et al.
The SPECT imaging shows the accumulation
of neural progenitor cells into internal organs
after systemic administration in middle cere-
bral  artery  occlusion  rats.  Neurosci  Lett.
2008;440(3):246-50.
43. Cao F, Li Z, Lee A, Liu Z, Chen K, Wang H,
et al. Noninvasive de novo imaging of human
embryonic stem cell-derived teratoma for-
mation. Cancer Res. 2009;69(7):2709-13.
44. Cai W, Chen X. Multimodality molecular im-
aging of tumor angiogenesis. J Nucl Med.
2008;49(Suppl 2):113S-128S.
45. Cai W, Niu G, Chen X. Imaging of integrins
as biomarkers for tumor angiogenesis. Curr
Pharm Des. 2008;14(28):2943-73.
46. Miller JC, Pien HH, Sahani D, Sorensen AG,
Thrall JH. Imaging angiogenesis: applica-
tions and potential for drug development. J
Natl Cancer Inst. 2005;97(3):172-87.
47. Winter PM, Caruthers SD, Kassner A, Harris
TD, Chinen LK, Allen JS, et al. Molecular im-
aging of angiogenesis in nascent Vx-2 rabbit
tumors using a novel alpha(nu)beta3-targeted
nanoparticle and 1.5 tesla magnetic resonance
imaging. Cancer Res. 2003;63(18):5838-43.
48. Schmieder AH, Winter PM, Caruthers SD, Har-
ris TD, Williams TA, Allen JS, et al. Molecular
MR imaging of melanoma angiogenesis with
alphanubeta3-targeted paramagnetic nanoparti-
cles. Magn Reson Med. 2005;53(3):621-7.
49. Beer AJ, Schwaiger M. Imaging of integrin
alphavbeta3 expression. Cancer Metastasis
Rev. 2008;27(4):631-44.
50. Indrevoll B, Kindberg GM, Solbakken M,
Bjurgert E, Johansen JH, Karlsen H, et al.
NC-100717: a versatile RGD peptide scaf-
fold for angiogenesis imaging. Bioorg Med
Chem Lett. 2006;16(24):6190-3.
51. Makowski MR, Ebersberger U, Nekolla S,
Schwaiger M. In vivo molecular imaging of
angiogenesis, targeting alphavbeta3 integrin
expression, in a patient after acute myocardial
infarction. Eur Heart J. 2008;29(18):2201.
52. Li S, Dobrucki LW, Sinusas AJ, Liu YH. A
new method for SPECT quantification of tar-
geted radiotracers uptake in the myocardium.
Med Image Comput Comput Assist Interv.
2005;8(Pt 2):684-91.
53. Lu E, Wagner WR, Schellenberger U, Abra-
ham JA, Klibanov AL, Woulfe SR, et al. Tar-
geted  in  vivo  labeling  of  receptors  for
vascular endothelial growth factor: approach
to identification of ischemic tissue. Circula-
tion. 2003;108(1):97-103.
54. Collingridge  DR,  Carroll  VA,  Glaser  M,
Aboagye EO, Osman S, Hutchinson OC, et
al. The Development of [(124)I] Iodinated-
VG76e: A Novel Tracer for Imaging Vascular
Endothelial Growth Factor in Vivo Using
Positron Emission Tomography 1. Cancer
Res. 2002;62(20):5912-9.
55. Li S, Peck-Radosavljevic M, Koller E, Koller
F, Kaserer K, Kreil A, et al. Characterization
of (123)I-vascular endothelial growth factor-
binding sites expressed on human tumour
cells: possible implication for tumour scintig-
raphy. Int J Cancer. 2001;91(6):789-96.
56. Wang T, Mancuso JJ, Kazmi SM, Dwelle J,
Sapozhnikova V, Willsey B, et al. Combined
two-photon luminescence microscopy and OCT
for macrophage detection in the hypercholes-
terolemic rabbit aorta using plasmonic gold
nanorose. Lasers Surg Med. 2012;44(1):49-59.
57. Owens DE 3rd, Peppas NA. Opsonization,
biodistribution,  and  pharmacokinetics  of
polymeric  nanoparticles.  Int  J.  Pharm.
2006;307(1):93-102.
58. Cai W, Chen K, Mohamedali KA, Cao Q,
Gambhir SS, Rosenblum MG, et al. PET of
Vascular Endothelial Growth Factor Receptor
Expression. J Nucl Med. 2006;47(12):2048-56.
59. Backer MV, Levashova Z, Patel V, Jehning
BT, Claffey K, Blankenberg FG, et al. Molec-
ular imaging of VEGF receptors in angiogenic
vasculature  with  single-chain VEGF-based
probes. Nat Med. 2007;13(4):504-9.
85 Stacy et al.: Targeted molecular imaging of angiogenesis60. Levashova  Z,  Backer  M,  Backer  JM,
Blankenberg FG. Imaging vascular endothe-
lial growth factor (VEGF) receptors in tur-
pentine-induced sterile thigh abscesses with
radiolabeled single-chain VEGF. J Nucl Med.
2009;50(12):2058-63.
61. Bengel FM, Anton M, Richter T, Simoes MV,
Haubner R, Henke J, et al. Noninvasive imaging
of transgene expression by use of positron emis-
sion tomography in a pig model of myocardial
gene transfer. Circulation. 2003;108(17):2127-33.
62. Wu JC. Molecular Imaging of the Kinetics of
Vascular Endothelial Growth Factor Gene Ex-
pression in Ischemic Myocardium. Circulation.
2004;110(6):685-91.
63. Wu JC. Positron Emission Tomography Imag-
ing of Cardiac Reporter Gene Expression in
Living Rats. Circulation. 2002;106(2):180-3.
64. Bach-Gansmo T, Danielsson R, Saracco A,
Wilczek B, Bogsrud T, Fangberget A, et al.
Integrin receptor imaging of breast cancer: a
proof-of-concept study to evaluate 99mTc-
NC100692. J Nucl Med. 2006;47(9):1434-9.
65. Edwards D, Jones P, Haramis H, Battle M, Lear
R, Barnett DJ, et al. 99mTc-NC100692--a tracer
for imaging vitronectin receptors associated
with angiogenesis: a preclinical investigation.
Nucl Med Biol. 2008;35(3):365-75.
66. Jaffer F, Libby P, Weissleder R. Molecular
imaging of cardiovascular disease. Circula-
tion. 2007;116(9):1052-61.
67. Almutairi A, Rossin R, Shokeen M, Hagooly
A, Ananth A, Capoccia B, et al. Biodegradable
dendritic positron-emitting nanoprobes for the
noninvasive imaging of angiogenesis. Proc
Natl Acad Sci USA. 2009;106(3):685-90. 
86 Stacy et al.: Targeted molecular imaging of angiogenesis